In the present study we sought to determine whether TLR9 stimulation by CpG ODNs can ameliorate not only Aβ related pathology but also tau related pathology, while concomitantly reducing oligomer levels in the 3xTg-AD mouse model. This evidence concerns the gene MAPT and Alzheimer disease.